Literature DB >> 20730489

Comparison of three culture media for the establishment of melanoma cell lines.

M C Pandolfino1, S Saïagh, A C Knol, B Dréno.   

Abstract

Melanoma cell lines are useful tools for the analysis of tumor-specific lymphocytes which are injected to patients treated by adoptive immunotherapy. So they have been established previously (with an efficacy of 47%) in Roswell Park Memorial Institute (RPMI) medium enriched with fetal calf serum (FCS). In order to improve the probability of establishing melanoma cell lines, we compared two FCS-free media with the original FCS medium. Ten melanoma-invaded lymph nodes were tested for their ability to grow in three different culture media: RPMI with FCS; RPMI with human serum (HS); serum-free X-vivo 15 (X15). For each medium, we compared the following criteria: percentage of lines obtained; period of establishment; cell morphology; expression of melanoma-associated antigens and surface molecules. More cell lines were obtained with HS and X15 media compared to FCS medium (7/10, 5/10 and 4/10, respectively). The time period to establish a stable line was similar for the three media. No morphological differences were observed in cells derived from the same tumor sample in the different media. With the X15 medium, cells generally expressed lower levels of melanocytic differentiation antigens and surface molecules. The growth of melanoma cell lines in FCS-free culture media appears possible and advantageous, with an increased probability of obtaining autologous tumor cell lines. Furthermore the cells obtained could be used as multiple antigenic sources in active or adoptive immunotherapy protocols.

Entities:  

Year:  2010        PMID: 20730489      PMCID: PMC2993863          DOI: 10.1007/s10616-010-9286-9

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  19 in total

Review 1.  Dendritic cell-based immunotherapy of cancer.

Authors:  L Zitvogel; E Angevin; T Tursz
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

2.  High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement.

Authors:  M C Pandolfino; N Labarrière; M H Tessier; A Cassidanius; S Bercegeay; P Lemarre; F Dehaut; B Dréno; F Jotereau
Journal:  Cancer Immunol Immunother       Date:  2001-05       Impact factor: 6.968

3.  LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal.

Authors:  S Le Guiner; E Le Dréan; N Labarrière; J F Fonteneau; C Viret; E Diez; F Jotereau
Journal:  Eur J Immunol       Date:  1998-04       Impact factor: 5.532

4.  Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription.

Authors:  N Labarriere; E Diez; M C Pandolfino; C Viret; Y Guilloux; S Le Guiner; J F Fonteneau; B Dreno; F Jotereau
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

5.  Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.

Authors:  Nathalie Labarrière; Marie-Christine Pandolfino; Nadine Gervois; Amir Khammari; Marie-Hélène Tessier; Brigitte Dréno; Francine Jotereau
Journal:  Cancer Immunol Immunother       Date:  2002-09-18       Impact factor: 6.968

6.  Loss of oncostatin M receptor beta in metastatic melanoma cells.

Authors:  A Lacreusette; J-M Nguyen; M-C Pandolfino; A Khammari; B Dreno; Y Jacques; A Godard; F Blanchard
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

7.  Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols.

Authors:  Annegret Vogl; Ute Sartorius; Thomas Vogt; Alexander Roesch; Michael Landthaler; Wilhelm Stolz; Bernd Becker
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

8.  Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.

Authors:  A Lacreusette; A Lartigue; J-M Nguyen; I Barbieux; M-C Pandolfino; F Paris; A Khammari; B Dréno; Y Jacques; F Blanchard; A Godard
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

9.  Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell cultures.

Authors:  Michal Lotem; Orly Yehuda-Gafni; Eliza Butnaryu; Olga Drize; Tamar Peretz; Dvorah Abeliovich
Journal:  Cancer Genet Cytogenet       Date:  2003-04-15

10.  HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes.

Authors:  E Le Dréan; N Gervois; E Diez; G Semana; B Dreno; F Jotereau
Journal:  Eur J Immunol       Date:  1995-10       Impact factor: 5.532

View more
  4 in total

Review 1.  The dark side of foetal bovine serum in extracellular vesicle studies.

Authors:  Ornella Urzì; Roger Olofsson Bagge; Rossella Crescitelli
Journal:  J Extracell Vesicles       Date:  2022-10

2.  Tissue biomarkers in melanoma patients treated with TIL.

Authors:  Anne-Chantal Knol; Jean-Michel Nguyen; Marie-Christine Pandolfino; Gaëlle Quéreux; Anabelle Brocard; Lucie Peuvrel; Mélanie Saint-Jean; Soraya Saiagh; Amir Khammari; Brigitte Dréno
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

3.  Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.

Authors:  Amir Khammari; Anne-Chantal Knol; Jean-Michel Nguyen; Céline Bossard; Marc-Guillaume Denis; Marie-Christine Pandolfino; Gaëlle Quéreux; Sylvain Bercegeay; Brigitte Dréno
Journal:  J Immunol Res       Date:  2014-01-08       Impact factor: 4.818

4.  Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.

Authors:  Mélanie Saint-Jean; Anne-Chantal Knol; Christelle Volteau; Gaëlle Quéreux; Lucie Peuvrel; Anabelle Brocard; Marie-Christine Pandolfino; Soraya Saiagh; Jean-Michel Nguyen; Christophe Bedane; Nicole Basset-Seguin; Amir Khammari; Brigitte Dréno
Journal:  J Immunol Res       Date:  2018-03-19       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.